Panmure Gordon (UK) Limited, an exempt principal trader, has disclosed its dealings in the securities of Allergy Therapeutics plc. On August 14, 2023, the company purchased 34,818 0.1p ordinary shares at a price of 0.02415 per unit and sold 79,744 0.1p ordinary shares at a price of 0.02508 per unit. No cash-settled derivative transactions or stock-settled derivative transactions were reported. No indemnity or option arrangements, agreements, or understandings relating to relevant securities were disclosed. The disclosure was made in accordance with Rule 8 of the Takeover Code.